Article Text
Abstract
Please confirm that an ethics committee approval has been applied for or granted: Yes: I’m uploading the Ethics Committee Approval as a PDF file with this abstract submission
Background and Aims The dexmedetomidine and tramadol were added as adjuvant to bupivacaine in transversus abdominis plane block (TAP).
Methods The study was carried out with 60 ASA I-II class participants aged 20-60 years who underwent laparoscopic cholecystectomy at Van Yüzüncü Yıl University Faculty of Medicine. Participants were randomized into two groups. -Group T (Adjuvant Tramadol): 40 mL of 0.250% bupivacaine +
1.5mg/kg and a maximum of 100 mg tramadol adjuvant -Group D (Adjuvant Dexmedetomidine): 40 mL of 0.250% bupivacaine + 0.5 mcg/kg and a maximum of 50 mcg dexmedetomidine adjuvant Standard general anesthesia was applied. After intubation, bilateral subcostal TAP block was performed by the same anesthesiologist, demographic data were recorded. Intraoperative vital signs of the participants (pulse, non-invasive blood pressure and peripheral oxygen saturation measurement), additional opioid and muscle relaxant needs, and complications were recorded. Extubation was performed after standard decurarization with atropine and neostigmine. Postoperative side effects (nausea, vomiting, pruritus, shivering), postoperative additional analgesic need, and 0 hour (Modified aldrete score ≥9 time was accepted as 0 hour), 3rd hour and 6th hour Visual Analogue Scale (VAS) scores were evaluated and recorded.
Results There was no statistically significant difference between the groups in terms of demographic data, intraoperative opioid consumption, muscle relaxant use, postoperative analgesic effects, side effects and postoperative mobilization time. (figures 1, 2).
Conclusions The dexmedetomidine as an adjuvant to bupivacaine in the bilateral subcostal TAP block will provide stable hemodynamics. It should be supported by studies with large participation.
Attachment zeki tez etik.pdf